Search Browse Earnings

SOLIGENIX, INC.

Nasdaq:SNGX

Pharmaceutical Preparations·PRINCETON, NJ

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

SOLIGENIX, INC. — SlamSEC

Revenue

$839,359

-11.5% YoY

FY 2024

Adj. EBITDA

-$7.6M

-909.7% margin

FY 2024

Net Income

-$6.1M

-731.6% margin

FY 2024

EPS (Diluted)

-$12.66

FY 2024

Stock Price

$1.20

+1.7%

2026-03-09

52W Range

$1.02 – $6.23

P/E Ratio

-0.1x

Market Cap

$12.1M

Cash

$18.7M

FY 2021

Total Debt

$1.3M

FY 2024

Net Cash

$17.3M

FY 2024

Enterprise Value

-$5.2M

Debt / EBITDA

2.3x

FY 2024

EV / EBITDA

0.7x

Employees

—